FIGURE 1 from Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer

ALDH1A3 overexpression in clinical gastric cancer treated by NAC and its implication for tumor growth. A, IHC of ALDH1A3 in FFPE tissues of 40 gastric cancer cases. Twenty cases treated by NAC with fluoropyrimidines and platinum agents, and 20 treatment-naïve controls were analyzed. Representative images of three NAC (−) and three NAC (+) specimens were shown. B, Quantitation of ALDH1A3 expression (H-score) in A. Details for the calculation are described in Materials and Methods. Western blot (C) and qRT-PCR (D) analyses of ALDH1A3 expression in mock and ALDH1A3-overexpressing (O/E) gastric cancer patient-derived JSC15-3 cells. In D, each column represents the mean ± SD of three technical replicates. Data are representative of at least three independent experiments. E, Effect of ALDH1A3 overexpression on xenografted tumor growth. NOD-SCID mice were subcutaneously implanted with mock and O/E JSC15-3 cells. At day 66 after implantation, tumor volumes were measured to evaluate the statistical significance of the difference between the groups. *, P < 0.05; **, P < 0.01, determined by the two-tailed t test.